Health Economics›Diffuse large B-cell lymphoma›Relapsed or refractory salvage therapy

Relapsed or refractory salvage therapy

Diffuse large B-cell lymphoma · 24 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
O-ICE Variant #01	—	R 1 550 925	21d	—	—	~3	~R 2 091 117 indirect	—
O-DHAP Variant #01	—	R 1 541 035	21d	—	—	3	R 2 061 446 PFS proxy	1
Glofit-GemOx Variant #01	—	R 199 620	21d	—	25.5 mo	11	R 1 508 885 PFS proxy	1
R-ICE Variant #01	—	R 90 307	21d	—	31.1 mo	3	R 141 397 PFS proxy	1
R-DHAP/R-VIM Variant #01	—	R 71 808	28d	—	—	~2	~R 101 753 indirect	—
R-DexaBEAM Variant #01 Partial	—	R 56 818	28d	—	—	~2	~R 113 636 indirect	—
R-IFE Variant #01	—	R 47 799	14d	—	—	~2	~R 95 598 indirect	—
R-NIMP Variant #01	—	R 41 642	28d	—	—	~3	~R 124 927 indirect	—
RICER Variant #01	—	R 40 312	14d	—	—	~2	~R 80 625 indirect	—
R-DHAOx Variant #02	—	R 30 938	21d	—	—	~4	~R 123 751 indirect	—
R-GDP Variant #01	—	R 30 037	21d	—	31.1 mo	6	R 180 224 PFS proxy	1
R-ESHAP Variant #01	—	R 30 009	—	—	31.1 mo	3	R 90 028 PFS proxy	1
R-DHAP Variant #01	—	R 29 945	21d	—	31.1 mo	3	R 89 835 PFS proxy	2
R-GemOx Variant #01	—	R 28 842	15d	3.8 mo	12.9 mo	8	R 230 735 PFS proxy	2
R-EPOCH Variant #01	—	R 28 380	21d	—	—	~6	~R 170 281 indirect	—
DHAP/VIM Variant #01	—	R 19 998	28d	—	—	~2	~R 24 038 indirect	—
HAM Variant #01	—	R 15 692	—	—	—	~1	~R 15 692 indirect	—
VIPD Variant #01	—	R 14 530	21d	—	—	~4	~R 58 119 indirect	—
EPIC (cisplatin) Variant #01	—	R 13 246	21d	—	—	~2	~R 26 493 indirect	—
EPIC (carboplatin) Variant #01	—	R 13 073	21d	—	—	~2	~R 26 146 indirect	—
MINE Variant #02	—	R 12 872	21d	—	—	~7	~R 90 104 indirect	—
DHAP Variant #01	—	R 2 495	28d	—	—	~10	~R 24 954 indirect	—
Axicabtagene ciloleucel monotherapy Variant #01 Partial	—	—	—	—	—	1	—	1
Lisocabtagene maraleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—

24 of 24 regimens shown